IPO - Imunon, Inc.

Form Type: S-1

Filing Date: 2025-04-04

Corporate Action: Ipo

Type: New

Accession Number: 000164117225002783

Filing Summary: Imunon, Inc. has filed a registration statement for an initial public offering (IPO) under Form S-1 with the SEC on April 4, 2025. The offering includes up to 10,000,000 shares of common stock, along with common warrants that allow purchasers to buy additional shares. The expected public offering price is set at $1.00 per share based on the last reported sale price on Nasdaq from April 3, 2025. The company has engaged Placement Agents to facilitate the offering, and shares are expected to be issued in a single closing. There is no guaranteed minimum amount of proceeds, which introduces financial risk, and the offering is subject to market conditions. Imunon aims to fund its operations through this IPO while highlighting the uncertainties regarding its financial condition and compliance with Nasdaq listing requirements. The company has noted that substantial doubt exists about its ability to continue as a going concern if it fails to regain compliance with Nasdaq's requirements by May 27, 2025. Investors should assess the high degree of risk associated with investing in this offering, as detailed in the prospectus.

Document Link: View Document

Form Type: DRS

Filing Date: 2025-03-19

Corporate Action: Ipo

Type: New

Accession Number: 000164117225000007

Filing Summary: Imunon, Inc. has submitted a confidential draft registration statement for an initial public offering (IPO) on March 19, 2025, under the Securities Act of 1933. This registration includes details about the proposed offering of shares of common stock and warrants to purchase additional shares. The offering will involve a maximum number of shares and warrants that are yet to be determined, with plans to raise capital through the sale of the securities. Key details about the offering include the structure, lead placement agents, and the contingent nature of the offering based on market reception and regulatory approval. The prospectus underscores potential risks such as compliance with Nasdaq's listing requirements and the company's ability to meet its business objectives. Investors are cautioned that the offering is subject to market conditions, and there is no minimum investment required, posing a risk that the offering could yield fewer proceeds than needed for business goals.

Document Link: View Document